Acquisition by Uzonwanne Jude of 115770 shares of MyMD Pharmaceuticals subject to Rule 16b-3
MYMDDelisted Stock | USD 1.82 0.02 1.09% |
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
MyMD |
Filed transaction by Mymd Pharmaceuticals Inc director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
MyMD Pharmaceuticals Fundamental Analysis
We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
MyMD Pharmaceuticals is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
MyMD Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
MyMD Pharmaceuticals Related Equities
UBX | Unity Biotechnology | 4.17 | ||||
RXRX | Recursion Pharmaceuticals | 3.58 | ||||
GOVX | GeoVax Labs | 2.26 | ||||
DSGN | Design Therapeutics | 2.25 | ||||
BOLT | Bolt Biotherapeutics | 2.00 | ||||
NVCT | Nuvectis Pharma | 1.53 | ||||
XBIO | Xenetic Biosciences | 1.47 | ||||
REPL | Replimune | 1.30 | ||||
KZR | Kezar Life | 0.94 | ||||
SRZN | Surrozen | 0.08 | ||||
AVIR | Atea Pharmaceuticals | 0.31 | ||||
LGND | Ligand Pharmaceuticals | 0.37 | ||||
KRON | Kronos Bio | 1.04 | ||||
LRMR | Larimar Therapeutics | 1.25 | ||||
PASG | Passage Bio | 1.52 | ||||
LYEL | Lyell Immunopharma | 1.61 | ||||
ORIC | Oric Pharmaceuticals | 1.68 | ||||
NBY | NovaBay Pharmaceuticals | 1.89 | ||||
GOSS | Gossamer Bio | 2.33 | ||||
KROS | Keros Therapeutics | 2.39 | ||||
REVB | Revelation Biosciences | 3.23 | ||||
LYRA | Lyra Therapeutics | 5.56 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Transaction History View history of all your transactions and understand their impact on performance | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |